Alnylam Pharmaceuticals (ALNY) Stock News, May-Aug 2025

Alnylam Pharmaceuticals (Nasdaq: ALNY) will present new data from its cardiovascular disease programs at the European Society of Cardiology (ESC) Congress 2025 in Madrid from August 29 - September 1, 2025. The presentations will feature data from two key programs:

1. The KARDIA-3 Phase 2 study of zilebesiran for uncontrolled hypertension, to be presented as a late-breaking abstract.

2. New analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran) in ATTR amyloidosis patients, including 12-month follow-up data and analysis of days lost to death and/or hospitalization.

The company will host an investor webcast to discuss the KARDIA-3 results on August 30, 2025, at 1:00 p.m. ET.

Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has announced its upcoming participation in the Canaccord Genuity 45th Annual Growth Conference. The company's management will deliver a corporate overview presentation on Tuesday, August 12, 2025, at 8:00 am ET.

Investors and interested parties can access a live audio webcast of the presentation through the Investors section of Alnylam's website. A replay will be made available within 48 hours following the event.

Alnylam Pharmaceuticals (Nasdaq: ALNY) reported strong Q2 2025 financial results, with total net product revenues of $672 million, representing 64% growth year-over-year. The growth was primarily driven by the TTR franchise, which generated $544 million in revenues (77% growth vs Q2 2024), including AMVUTTRA's successful ATTR-CM launch with approximately 1,400 patients.

The company secured multiple global regulatory approvals for AMVUTTRA in ATTR-CM, including in the EU, Brazil, UK, and Japan. Based on strong H1 2025 performance, Alnylam raised its 2025 guidance, projecting TTR franchise revenues of $2.175-$2.275 billion and total net product revenues of $2.65-$2.8 billion, a 27% increase at midpoint.

Q2 2025 financial highlights include total revenues of $773.7 million (17% growth) and a GAAP net loss of $0.51 per share. The company maintained a strong financial position with $2.86 billion in cash and investments as of June 30, 2025.

Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has scheduled its second quarter 2025 financial results announcement for Thursday, July 31, 2025, before U.S. markets open.

Management will host a conference call at 8:30 AM ET on the same day to discuss Q2 results and future outlook. Investors can access the live audio webcast through the Investors section at www.alnylam.com/events, with an archived version available approximately two hours after the event.

Alnylam Pharmaceuticals (ALNY) has promoted Pushkal Garg, M.D., to Executive Vice President, Chief Research and Development Officer to lead an integrated R&D organization. Following the successful launch of AMVUTTRA for ATTR-CM, this strategic move aims to accelerate pipeline development through enhanced collaboration and faster decision-making. Dr. Garg, who joined Alnylam in 2014, brings extensive experience from Bristol-Myers Squibb and Millennium Pharmaceuticals. Under his leadership, Alnylam aims to deliver RNAi therapeutics to all major tissues by 2030, building on their track record of multiple drug approvals and positive Phase 3 results. The company sees this integration as crucial for scaling their impact in treating various diseases lacking effective treatments.

Alnylam Pharmaceuticals (ALNY) has received European Commission approval for AMVUTTRA (vutrisiran) to treat ATTR amyloidosis with cardiomyopathy, making it the first RNAi therapeutic approved for this condition in Europe. The approval is based on the HELIOS-B Phase 3 study results, which demonstrated a 28% reduction in composite all-cause mortality and cardiovascular events, and up to 36% reduction in all-cause mortality through 42 months. The drug, administered quarterly, showed significant improvements in functional capacity and quality of life. AMVUTTRA works by reducing disease-causing TTR protein, addressing approximately 100,000 affected patients across Europe. The approval follows recent authorizations in the U.S. and Brazil, with similar safety profiles to placebo in clinical trials.

Alnylam Pharmaceuticals (ALNY), a leader in RNAi therapeutics, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will deliver a corporate presentation on June 9, 2025, at 9:20 am ET. Investors and interested parties can access a live audio webcast through the Investors section of Alnylam's website at www.alnylam.com/events. A replay of the presentation will be made available within 48 hours after the event.

Alnylam Pharmaceuticals (NASDAQ: ALNY) has released its 2024 Corporate Responsibility Report, focusing on "Accepting Challenges to Improve the Health of Humanity." The report showcases significant progress across six corporate responsibility pillars, highlighting environmental stewardship, patient access, and health equity initiatives.

Key achievements include: independently verified data on GHG emissions (Scope 1, 2, and 3), implementation of 100% renewable energy at Norton and Alewife manufacturing sites, advancement of their Patient Access Philosophy, and expansion of the Alnylam Challengers global health equity initiative. The company's culture survey revealed strong employee satisfaction, with 88% of employees feeling accepted and treated fairly.

Alnylam Pharmaceuticals (ALNY) presented compelling new data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran) for treating ATTR amyloidosis with cardiomyopathy at Heart Failure 2025 Congress. The analysis showed significant reductions in mortality and cardiovascular events: - 36% reduction in all-cause mortality risk through 42 months - 33% reduction in cardiovascular mortality risk - 46% reduction in urgent heart failure visits - 33% reduction in heart failure hospitalizations - 27% reduction in cardiovascular events - 25% reduction in cardiovascular hospitalizations The results were simultaneously published in JACC, with vital status confirmed for over 99% of patients. AMVUTTRA has received FDA and ANVISA approval for ATTR-CM treatment, with EMA approval expected by Q3 2025. The company also announced plans for TRITON-CM, a Phase 3 study of their next-generation RNAi therapeutic nucresiran.